Evidence mapPaperPMID 41524842Full record

ArticleCell biochemistry and biophysics2026

Erythropoietin-derived Non-erythropoietic Peptides Conferring Oxidative Stress Resistance to Keratinocytes and Fibroblasts.

Min Ae Han, Janbolat Ashim, Youngheum Ji, Eunho Kang, Minchan Jeong, Sung Jae Kim, Wookyung Yu, Jin Hae Kim, Cheil Moon, Chang-Hun Lee

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Min Ae HanDepartment of New Biology, Daegu Gyeongbuk Institute of Science and Technology, 333 Technojungang-daero, DGIST, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea.
Janbolat AshimDepartment of Brain Sciences, Daegu Gyeongbuk Institute of Science and Technology, 333 Technojungang-daero, DGIST, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea.
Youngheum JiDepartment of New Biology, Daegu Gyeongbuk Institute of Science and Technology, 333 Technojungang-daero, DGIST, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea.
Eunho KangDepartment of New Biology, Daegu Gyeongbuk Institute of Science and Technology, 333 Technojungang-daero, DGIST, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea.
Minchan JeongDepartment of New Biology, Daegu Gyeongbuk Institute of Science and Technology, 333 Technojungang-daero, DGIST, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea.
Sung Jae KimDepartment of Orthopedic Surgery, College of Medicine, Hanyang University, 222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea.
Wookyung YuDepartment of Brain Sciences, Daegu Gyeongbuk Institute of Science and Technology, 333 Technojungang-daero, DGIST, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea.
Jin Hae KimDepartment of New Biology, Daegu Gyeongbuk Institute of Science and Technology, 333 Technojungang-daero, DGIST, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea.
Cheil MoonDepartment of Brain Sciences, Daegu Gyeongbuk Institute of Science and Technology, 333 Technojungang-daero, DGIST, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea. cmoon@dgist.ac.kr.
Chang-Hun LeeDepartment of New Biology, Daegu Gyeongbuk Institute of Science and Technology, 333 Technojungang-daero, DGIST, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea. leech@dgist.ac.kr.

Funding

the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea RS-3-KH141178; HP23C0104
6 · The paper itself

Abstract

Erythropoietin (EPO) exerts tissue-protective effects; however, its erythropoietic activity limits broader use. Three EPO-derived peptides (ML1-C1/C2/C3) were designed from the C-helix of EPO to remove erythropoietic activity while retaining cell-protective activity. Circular dichroism and nuclear magnetic resonance spectroscopies were used to assess the solution structures of ML1-C1/C2/C3 peptides. The peptide activities for cytoprotection and growth support were assessed using skin-relevant cells, HaCaT cells and 3T3-L1 cells, which proposes an effect on skin epithelial keratinocytes and pre-adipocytic fibroblasts, respectively. Also, an erythroid-precursor cell line, TF-1, was used to evaluate the erythropoietic function of the three peptides. Spectroscopic analyses of ML1-C1/C2/C3 peptides revealed similar secondary structures and different flexibilities between the peptides. While ML1-C1 and ML1-C3 had highly flexible loop-like structures, ML1-C2 had less flexible loop-like structures. Also, their cellular effects vary in a cell type-dependent manner. The EPO-derived peptides can attenuate H₂O₂-induced loss of viability in HaCaT cells and 3T3-L1 cells. Under low-serum conditions, the three peptides promoted HaCaT proliferation, whereas only ML1-C1 improved 3T3-L1 proliferation. In TF-1 cells, none of the peptides increased cell viability or hemoglobin staining, whereas recombinant human EPO did, indicating the lack of erythropoietic activity of the peptides under experimental conditions. These findings support the potential of EPO-derived peptides as skin-protective agents and motivate future work for skin therapeutics or cosmetic purposes.

Indexed as

ErythropoietinFibroblastsKeratinocytesOxidative StressPeptides3T3-L1 CellsAmino Acid SequenceAnimalsCell LineCell ProliferationCell SurvivalHaCaT CellsHumansHydrogen PeroxideMiceProtein Structure, SecondaryErythropoietinHydrogen PeroxidePeptidesErythropoiesisErythropoietinFibroblastKeratinocyteOxidative stressProliferationSkin

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.